

## FURTHER DETAIL ON BARD1'S US SALES STRATEGY

**Melbourne, Australia, 1 December 2020:** Further to BARD1 Life Sciences Limited's (ASX:BD1) (**BARD1** or **Company**) ASX announcement on 23 November 2020, BARD1 would like to clarify that it has been notified by its U.S. distributor, StatLab Medical Products (**StatLab**), that they have converted one of their high volume customers to the hTERT test, with direct technical support from BARD1. This new customer is a key existing growth customer of StatLab. The hTERT test is antibody test that detects hTERT to assist in the diagnosis of bladder cancer. This new customer has placed and received their first order of the hTERT product from StatLab (which is not considered material). StatLab supplies various products, including hTERT, to its customers under its standard terms and conditions. This customer is not required to purchase a minimum quantity of product from StatLab, nor does it have any binding commitments and therefore the financial benefit is unable to be quantified at this stage. The Company confirms that it has not signed a direct contract with this customer or entered into any new distribution arrangements with StatLab.

As outlined in our announcement on 23 November 2020, the Company is encouraged by the adoption of the hTERT test by StatLab's customer and it is an indication that the revised sales strategy in the USA is working.

*Authorised by the Company Secretary, Tony Di Pietro.*

- ENDS -

### COMPANY CONTACTS

**Dr Leearne Hinch**  
CEO

**E** [leearne@bard1.com](mailto:leearne@bard1.com)

**M** +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman

**E** [geoff.cumming@bard1.com](mailto:geoff.cumming@bard1.com)

**M** +61 417 203 021

## **ABOUT BARD1 LIFE SCIENCES LTD**

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

## **FORWARD LOOKING STATEMENTS**

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.